Monte Rosa Therapeutics, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. The company is an early-stage biotechnology business developing small-molecule molecular glue degraders using its QuEEN protein-degradation platform. It had no approved products and reported no product revenue.
Financial highlights
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $14.6 million | $4.9 million | $23.9 million | $8.7 million |
| General and administrative | $3.5 million | $0.5 million | $5.7 million | $1.0 million |
| Total operating expenses | $18.1 million | $5.4 million | $29.6 million | $9.7 million |
| Net loss | $18.4 million | $5.4 million | $30.7 million | $9.7 million |
| Basic and diluted net loss per share | $3.63 | $3.64 | $9.03 | $6.69 |
For the six months ended June 30, operating cash used was $27.4 million, capital expenditures were $4.9 million, and financing cash provided was $348.2 million. Cash and cash equivalents were $357.1 million at June 30, 2021, versus $41.7 million at December 31, 2020; restricted cash was an additional $1.7 million. Total assets were $368.9 million and total liabilities were $12.3 million. The balance sheet reported no debt; management stated it had no credit facility or committed external funding source. No operating margin is meaningful because the company had no revenue.
Changes and notable transactions
- Q2 operating expenses more than tripled year over year, reflecting expanded research activity, staffing, laboratory costs and facilities. R&D rose by $9.8 million and G&A by $2.9 million. Six-month net loss increased by $21.0 million year over year.
- The June IPO issued 11.7 million shares at $19 per share and generated $203.9 million net proceeds. The company also raised $48 million gross through Series B preferred stock in February and $95 million gross through Series C preferred stock in March. Preferred shares converted into common stock in connection with the IPO.
- In July, underwriters exercised the IPO overallotment option in full, generating a further $31.0 million net proceeds from 1.755 million shares. This was a subsequent event, not included in June 30 cash.
- Property and equipment, net, increased to $8.9 million from $4.6 million at year-end 2020, consistent with operational expansion.
Outlook, risks and unusual items
- Management expected existing cash and cash equivalents to fund operating expenses and capital requirements for at least 12 months from issuance of the financial statements. Separately, the risk discussion estimated that IPO proceeds and existing cash would fund operations into the third quarter of 2024, assuming no additional collaboration or strategic-alliance funding. Both estimates depend on assumptions and spending could exceed expectations; further funding will be needed for development.
- Management expects R&D, G&A and capital expenditures to rise as programs advance. The company planned to submit an IND for a GSPT1-directed candidate in the first half of 2022. All programs were still in preclinical discovery; no clinical trials had begun.
- Key risks include the uncertainty and cost of drug discovery and clinical development, the novel QuEEN approach, reliance on third-party research and manufacturers, future financing needs and potential dilution, competition, and possible COVID-19-related disruption. Operations had not been significantly affected by COVID-19 as of the filing, though future effects were uncertain.
- The company reported no issued patents; its patent applications were at an early prosecution stage. It also reported material weaknesses in financial reporting controls and concluded disclosure controls were ineffective at quarter-end. Remediation efforts were ongoing.
- Foreign-exchange losses were $0.3 million in Q2 and $0.1 million for the six-month period, primarily related to Swiss operations. Six-month results also included a $1.0 million expense from the fair-value change in preferred-stock tranche obligations, settled in February.
- Ridgeline Therapeutics, a related party, received $7.3 million in payments during the first half. The company terminated its Ridgeline services agreement on August 9, 2021, stating that functions previously provided were brought in-house.
Important facts for investors to verify
- Whether the planned GSPT1 IND submission and preclinical development milestones remain on schedule, and what evidence supports advancement.
- Cash runway assumptions underlying the stated third-quarter 2024 estimate, including expected spending, capital needs and the effect of the July overallotment proceeds.
- Progress in remediating material weaknesses and whether disclosure controls become effective.
- Status, scope and prosecution progress of patent applications, given that no patents had issued as of the filing.
- Transition of research and administrative work from Ridgeline in-house, including costs, continuity and related-party arrangements.